Biond Biologics Ltd Is A Clinical Stage Biotechnology Company Dedicated To Developing Innovative Immunotherapies And Drug Delivery Platforms For Cancer Treatmentfounded In 2016 By Tehila Ben Mosheori Shiloand A Team Of Expertsbiond Focuses On Addressing Unmet Needs In Oncology Through Scientific Innovation And Entrepreneurial Leadership The Company Has A Robust Immunotherapy Pipeline That Includes Bnd 22A Multi Cell Checkpoint Inhibitor Targeting Ilt2And Bnd 35An Anti Ilt3 Lilrb4 Antibody Currently In Phase 1 Trialsbiond Also Offers The Inspire Platforma Ph Sensitive Delivery System Designed To Enhance The Precision Of Drug Delivery Into Cancer Cellsheadquartered In Israelbiond Is Also Active In Estonia S Biotech Ecosystemreflecting Its Commitment To Advancing Cancer Therapeutics And Improving Patient Outcomes
